Allergan's Botox Off-Label Promotion Suit Raises Questions, But Why Would Wall Street Care?
This article was originally published in RPM Report
Executive Summary
Allergan's lawsuit against FDA over post-marketing safety restrictions for Botox is yet another new wrinkle that may help define the significance of the new "Safety First" regulatory era. But there is more to this case than meets the eye.
You may also be interested in...
Declaring Victory: How FDA Releases REMS
There is a new category of FDA action letter: a REMS release. Dozens of sponsors of “MedGuide-only” REMS received them after an FDA policy change. But now, FDA is issuing them regularly to sponsors whose communication plans have met their goals – or at least run their course.
FDA Overreaches in Jurisdictional Power Grab
Letter to Dysport clinical investigator claims promotional violations in magazine interviews. Do clinical investigators really sign away their right to free speech when they conduct a clinical trial for a drug company?
FDA Overreaches in Jurisdictional Power Grab
Letter to Dysport clinical investigator claims promotional violations in magazine interviews. Do clinical investigators really sign away their right to free speech when they conduct a clinical trial for a drug company?